<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Drug Manufacturers &#8211; Major</title>
	<atom:link href="http://www.stockbloghub.com/category/drug-manufacturers-major/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AZN) US Court Rejects AstraZeneca&#8217;s Case</title>
		<link>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196</link>
		<comments>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196#comments</comments>
		<pubDate>Thu, 19 Apr 2012 20:24:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97196</guid>
		<description><![CDATA[Recently, AstraZeneca (AZN) announced that US District Court for the District of Columbia has dismissed the lawsuit filed by the company against the US Food and Drug Administration (FDA). AstraZeneca had taken legal action against the FDA, challenging the agency’s decision to reject AstraZeneca’s Citizen Petitions. The Citizen Petitions were filed by the company for Seroquel (quetiapine fumarate) and Seroquel XR. The Citizen Petitions were filed to bar the FDA from approving any generic versions of the drug that do not include warnings related to hyperglycemia and suicidality in its label. With this move, AstraZeneca was looking to delay the launch of generic versions of Seroquel considering the company has marketing exclusivity for the data associated with the hyperglycemia warning till December 2, 2012. Meanwhile, the UK High Court has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Healthcare Reform: Bad News for Big Pharma?</title>
		<link>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425</link>
		<comments>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:56:03 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97425</guid>
		<description><![CDATA[Healthcare reform could be a minefield for Big Pharma in the long run. The Patient Protection and Affordable Care Act – less fondly known as “Obamacare” – was the big story to close out the month of March, as the Supreme Court officially took the case. In an effort to figure out which way the vote was going to swing, the media analyzed every word, pause and twitch the justices made. Though all of that heavy-duty analysis doesn’t actually prove anything; while the Court has likely already decided the healthcare mandate’s fate one way or the other, “We the People” probably won’t find out until June. Considering the political left’s repeated complaints about Solicitor General Donald Verrilli Jr. and Deputy Attorney General Edwin S. Kneedler’s admittedly painful performance in explaining ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson &amp; Johnson Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2012/02/06/jnj-johnson-johnson-earnings-scorecard/91297</link>
		<comments>http://www.stockbloghub.com/2012/02/06/jnj-johnson-johnson-earnings-scorecard/91297#comments</comments>
		<pubDate>Mon, 06 Feb 2012 17:32:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91297</guid>
		<description><![CDATA[Following the release of fourth quarter and full year 2011 results, most of the analysts covering Johnson &#38; Johnson (JNJ) have reduced their earnings estimates for 2012 and 2013. The revisions in estimates mainly reflect the guidance provided by the company. Fourth Quarter and Full Year 2011 Recap Johnson &#38; Johnson posted fourth quarter 2011 earnings (excluding special items) of $1.13 per share, three cents above the Zacks Consensus Estimate of $1.10 and 9.7% above the year-ago earnings of $1.03.. Johnson &#38; Johnson’s revenues for the fourth quarter increased 3.9% year-over-year to $16.3 billion. Revenues were in-line with the Zacks Consensus Estimate. Full year 2011 earnings came in at $5.00, 5% above the year-ago earnings of $4.76 per share and 4 cents above the Zacks Consensus Estimate. Earnings came in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/06/jnj-johnson-johnson-earnings-scorecard/91297/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Earnings Season in Full Swing &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2012/01/24/abt-earnings-season-in-full-swing-earnings-preview/90668</link>
		<comments>http://www.stockbloghub.com/2012/01/24/abt-earnings-season-in-full-swing-earnings-preview/90668#comments</comments>
		<pubDate>Tue, 24 Jan 2012 17:21:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ADP]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Automatic Data Processing Inc]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Colgate-Palmolive Company]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[DeVry Inc.]]></category>
		<category><![CDATA[DV]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[JNPR]]></category>
		<category><![CDATA[Juniper Networks Inc.]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90668</guid>
		<description><![CDATA[Earnings Preview 1/20/12 Earnings season will be in full swing this week. 422 firms are scheduled to report, and 117 of those will be members of the S&#38;P 500. By the end of the week we should have a very good handle on just how weak or strong this earnings season will be. The firms reporting next week read like a who’s who of American industry.  They.include: Abbott Labs (ABT), Apple (AAPL), Automatic Data Processing (ADP), AT&#38;T (T), Boeing  (BA), Bristol Myers (BMY), Caterpillar (CAT), CSX (CSX), Chevron (CVX), Colgate Palmolive (CL), Conoco Phillips (COP &#8211; Analyst Report) and DuPont (DD) – and that is just in the first four letters of the alphabet! It will also be a moderate week for economic data.  Things will be slow early in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/24/abt-earnings-season-in-full-swing-earnings-preview/90668/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Mixed Earnings, Greece May Slip Markets</title>
		<link>http://www.stockbloghub.com/2012/01/24/jnj-mixed-earnings-greece-may-slip-markets/90717</link>
		<comments>http://www.stockbloghub.com/2012/01/24/jnj-mixed-earnings-greece-may-slip-markets/90717#comments</comments>
		<pubDate>Tue, 24 Jan 2012 17:20:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Coach Inc.]]></category>
		<category><![CDATA[COH]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90717</guid>
		<description><![CDATA[With nothing major on the domestic economic calendar, headlines about Greece’s as-yet unsuccessful negotiations with its bondholders to restructure its private debt may get some traction. But today’s market action will be mostly about the slew of mixed earnings reports from a &#8220;who’s who&#8221; of corporate America. We also have President Obama’s State of the Union address later this evening. We have 5 Dow components reporting results this morning, of which three came out with positive surprises, while two came up short. Johnson &#38; Johnson (JNJ) came out with a positive EPS surprise on in-line revenue numbers. McDonald’s (MCD) beat earnings expectations on roughly in-line revenue numbers. DuPont (DD) came out with a modest earnings surprise, though the chemicals giant’s top-line came short of expectations. The company had lowered expectations ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/24/jnj-mixed-earnings-greece-may-slip-markets/90717/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Jan 24: Day of Earnings! &#8211; Economic Highlights</title>
		<link>http://www.stockbloghub.com/2012/01/24/jnj-jan-24-day-of-earnings-economic-highlights/90730</link>
		<comments>http://www.stockbloghub.com/2012/01/24/jnj-jan-24-day-of-earnings-economic-highlights/90730#comments</comments>
		<pubDate>Tue, 24 Jan 2012 17:19:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Coach Inc.]]></category>
		<category><![CDATA[COH]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90730</guid>
		<description><![CDATA[With nothing major on the domestic economic calendar, headlines about Greece’s as-yet unsuccessful negotiations with its bondholders to restructure its private debt may get some traction. But today’s market action will be mostly about the slew of mixed earnings reports from a &#8220;who’s who&#8221; of corporate America. We also have President Obama’s State of the Union address later this evening. We have 5 Dow components reporting results this morning, of which three came out with positive surprises, while two came up short. Johnson &#38; Johnson (JNJ) came out with a positive EPS surprise on in-line revenue numbers. McDonald’s (MCD) beat earnings expectations on roughly in-line revenue numbers. DuPont (DD) came out with a modest earnings surprise, though the chemicals giant’s top-line came short of expectations. The company had lowered expectations ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/24/jnj-jan-24-day-of-earnings-economic-highlights/90730/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals</title>
		<link>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883</link>
		<comments>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883#comments</comments>
		<pubDate>Mon, 09 Jan 2012 16:34:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89883</guid>
		<description><![CDATA[The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&#38;A) deals have taken place in the pharma sector over the last couple of years. With most of the big pharma players already facing or likely to face generic threats to their key products, the companies are resorting to M&#38;As and in-licensing deals to counter the loss of revenues that will arise following the genericization of its key drugs. Pharma major Bristol-Myers is no exception as the generic threat looms over many of its key drugs, including the blockbuster blood-thinner Plavix, co-developed with Sanofi (SNY). Bristol-Myers is looking to combat the generic threat through partnering deals and acquisitions, and is introducing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Company News for January 04, 2012 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2012/01/08/bmy-company-news-for-january-04-2012-corporate-summary/89648</link>
		<comments>http://www.stockbloghub.com/2012/01/08/bmy-company-news-for-january-04-2012-corporate-summary/89648#comments</comments>
		<pubDate>Mon, 09 Jan 2012 04:48:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[China Petroleum & Chemical Corporation]]></category>
		<category><![CDATA[Devon Energy Corporation]]></category>
		<category><![CDATA[DVN]]></category>
		<category><![CDATA[Mead Johnson Nutrition Company]]></category>
		<category><![CDATA[MGIC Investment Corporation]]></category>
		<category><![CDATA[MJN]]></category>
		<category><![CDATA[MTG]]></category>
		<category><![CDATA[Rambus Inc.]]></category>
		<category><![CDATA[RMBS]]></category>
		<category><![CDATA[SNP]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[United States Steel Corporation]]></category>
		<category><![CDATA[X]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89648</guid>
		<description><![CDATA[•    Share prices of natural gas producer Devon Energy Corp (NYSE:DVN) gained 6.63% after the company announced it would sell a stake in five of its exploratory projects across the U.S., to Sinopec International Petroleum Exploration &#38; Production, a unit of China Petroleum &#38; Chemical (NYSE:SNP) for $2.2 billion •    Pediatric nutrition company Mead Johnson Nutrition Co.’s (NYSE:MJN) shares advanced 3.81% to close at $71.35 after U.S. health officials confirmed they hadn’t found deadly bacteria in cans of the company&#8217;s Enfamil baby formula •    Shares of technology-licensing company Rambus Inc. (NASDAQ:RMBS) increased 7.42% to close at $8.11 after the company raised its forecast for the fourth quarter •    Steel producer U.S. Steel Corp.’s (NYSE:X) shares rose 6.46% after a better U.S. manufacturing activity report, striking a six-month high during the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/08/bmy-company-news-for-january-04-2012-corporate-summary/89648/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Sees Pipeline Setback</title>
		<link>http://www.stockbloghub.com/2011/12/24/bmy-bristol-myers-squibb-sees-pipeline-setback/89198</link>
		<comments>http://www.stockbloghub.com/2011/12/24/bmy-bristol-myers-squibb-sees-pipeline-setback/89198#comments</comments>
		<pubDate>Sat, 24 Dec 2011 15:13:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[BSC]]></category>
		<category><![CDATA[ELEMENTS BG Small Cap ETN]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89198</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (BMY) recently suffered a pipeline setback with its oncology candidate, brivanib, performing disappointingly in a late-stage study (BRISK-PS). The study evaluated brivanib as a combination therapy in liver cancer patients who had either failed or were intolerant to Onyx Pharmaceuticals, Inc. / Bayer’s (ONXX/BAYRY) Nexavar. Results from the multicenter, double-blind, randomized study revealed that there was no improvement in the overall survival rate for patients treated with brivanib and the best supportive care (BSC) versus those in the placebo plus BSC arm. Bristol-Myers intends to present detailed data from the study at an upcoming scientific conference. The disappointing results of the BRISK-PS study notwithstanding, Bristol-Myers intends to continue evaluating the liver cancer candidate in three other late-stage studies. Bristol-Myers stated that it has conducted 29 studies till ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/24/bmy-bristol-myers-squibb-sees-pipeline-setback/89198/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis&#8217; Cancer Drug Afinitor Shows Promise for Breast Cancer</title>
		<link>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414</link>
		<comments>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414#comments</comments>
		<pubDate>Mon, 12 Dec 2011 22:12:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PFS]]></category>
		<category><![CDATA[Provident Financial Services Inc]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88414</guid>
		<description><![CDATA[Novartis’ (NVS) cancer drug Afinitor took a significant step forward, as the company once again presented encouraging data from late-stage trials of Afinitor for the treatment of breast cancer, an indication for which management estimates sales potential in excess of $1 billion. Afinitor is not yet approved for the treatment of breast cancer. The pivotal late-stage study (BOLERO-2) evaluated the use of Afinitor in combination with Pfizer’s (PFE) Aromasin (a hormonal therapy) in postmenopausal women with metastatic breast cancer whose disease has progressed, despite treatment with hormonal therapies like Novartis’ Femara or AstraZeneca’s (AZN) Arimidex. The long-term data showed that Afinitor plus Aromasin expanded progression-free survival (PFS), or time, without causing tumor growth in patients, by more than two times versus Aromasin alone. Treatment with Afinitor improved the PFS to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Drug Cleared by the European Commission</title>
		<link>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920</link>
		<comments>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920#comments</comments>
		<pubDate>Thu, 08 Dec 2011 19:01:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87920</guid>
		<description><![CDATA[AstraZeneca (AZN) and its partner Bristol-Myers Squibb (BMY) announced recently that Komboglyze has been approved by the European Commission (EC) in European Union (EU). Komboglyze is a combination of Onglyza (saxagliptin), a DPP-4 inhibitor and metformin, a generic drug for type II diabetes. AstraZeneca has co-developed Onglyza with Bristol-Myers. The EC cleared Komboglyze as an adjunct to diet and exercise to improve glycemic control in adults suffering from type II diabetes. Komboglyze is indicated for patients who show inadequate response to the maximum tolerated dose of metformin alone or those already being treated with the combination of Onglyza and metformin as separate tablets. Komboglyze is expected to provide single pill dosing convenience to patients currently taking Onglyza and metformin seperately. We remind investors that Komboglyze was approved by the US ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Spotlight on Hepatitis-C Market</title>
		<link>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141</link>
		<comments>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141#comments</comments>
		<pubDate>Wed, 07 Dec 2011 17:52:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88141</guid>
		<description><![CDATA[Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to have caught the eye of several pharma/biotech companies &#8211; as evident by the deals being signed for the development of drugs for the treatment of HCV. We are talking about the recent announcements made by big players like Johnson &#38; Johnson (JNJ), Bristol-Myers Squibb (BMY) and Gilead Sciences, Inc. (GILD). All three companies have made it clear they want a piece of the HCV market pie. Johnson &#38; Johnson’s Tibotec Pharmaceuticals and Bristol-Myers Squibb recently announced that they have decided to join forces for the development of Bristol-Myers’ daclatasvir (BMS-790052) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Watson Pharmaceuticals Joins Pfizer for Generic Lipitor</title>
		<link>http://www.stockbloghub.com/2011/12/06/pfe-watson-pharmaceuticals-joins-pfizer-for-generic-lipitor/88086</link>
		<comments>http://www.stockbloghub.com/2011/12/06/pfe-watson-pharmaceuticals-joins-pfizer-for-generic-lipitor/88086#comments</comments>
		<pubDate>Tue, 06 Dec 2011 17:06:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88086</guid>
		<description><![CDATA[November 30, 2011 was a big day for Pfizer, Inc. (PFE) with its blockbuster cholesterol drug, Lipitor, losing exclusivity in the US. With so many drugs losing exclusivity, why is the loss of exclusivity of Lipitor such a major event? Well, Lipitor has been a huge revenue generator and its loss of exclusivity could very well represent the biggest generic opportunity in recent times. Lipitor sales came in at $10.7 billion in 2010 with sales for the first nine months of 2011 coming in at $7.6 billion. Pfizer Goes Aggressive Typically, whenever a branded drug loses exclusivity, it witnesses a rapid erosion in sales with the entry of generic versions. However, Pfizer is trying to turn the tide in its favor by adopting several steps to minimize the impact of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/06/pfe-watson-pharmaceuticals-joins-pfizer-for-generic-lipitor/88086/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis&#8217; Rasitrio Cleared in European Union</title>
		<link>http://www.stockbloghub.com/2011/11/28/nvs-novartis-rasitrio-cleared-in-european-union/87648</link>
		<comments>http://www.stockbloghub.com/2011/11/28/nvs-novartis-rasitrio-cleared-in-european-union/87648#comments</comments>
		<pubDate>Mon, 28 Nov 2011 20:34:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87648</guid>
		<description><![CDATA[Novartis (NVS) recently announced that its triple combination hypertension pill Rasitrio has been cleared in the European Union (EU). Rasitrio combines the currently marketed hypertension pill Razilez (marketed as Tekturna in the US) with amlodipine and hydrochlorothiazide (HCT). The pill is already marketed as Amturnide in the US. The approval of Rasitrio was based on data from late stage trials which showed that the drug significantly reduced blood pressure as compared to dual combinations of each of its individual components. The positive effect of Rasitrio was seen within a week of starting treatment and was maintained for the entire 24-hour dose interval. The approval of Rasitrio is a definite boon for sufferers of hypertension as most (almost 85%) have to recourse to multiple medicines to control their blood pressure. Novartis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/nvs-novartis-rasitrio-cleared-in-european-union/87648/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Bayer Cut to Underperform</title>
		<link>http://www.stockbloghub.com/2011/11/23/jnj-bayer-cut-to-underperform/87425</link>
		<comments>http://www.stockbloghub.com/2011/11/23/jnj-bayer-cut-to-underperform/87425#comments</comments>
		<pubDate>Wed, 23 Nov 2011 17:23:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87425</guid>
		<description><![CDATA[We recently downgraded Bayer (BAYRY) to Underperform from Neutral purely on valuation grounds. We believe that the stock is overvalued at current levels. Even though the US Food and Drug Administration (FDA) cleared Bayer/ Johnson &#38; Johnson’s (JNJ) potential blockbuster blood thinner Xarelto for stroke prevention in atrial fibrillation (SPAF) earlier in the month, the associated warning that discontinuation of the drug increases the risk of stroke in SPAF patients could hamper its sales. Below-par showing by Xarelto could pull down the stock significantly. Moreover, the presence of Boehringer Ingelheim’s Pradaxa (approved by the FDA in 2010) has intensified competition in the market. Moreover, Bayer delivered average results in the third quarter of 2011 with key drugs such as Betaferon, Kogenate and Levitra not performing well. Sales in the Pharmaceutical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/23/jnj-bayer-cut-to-underperform/87425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson &amp; Johnson 2011 Third Quarter Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2011/11/06/jnj-johnson-johnson-2011-third-quarter-earnings-scorecard/86234</link>
		<comments>http://www.stockbloghub.com/2011/11/06/jnj-johnson-johnson-2011-third-quarter-earnings-scorecard/86234#comments</comments>
		<pubDate>Mon, 07 Nov 2011 00:13:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86234</guid>
		<description><![CDATA[Following the release of third quarter 2011 results, majority of the analysts covering Johnson &#38; Johnson (JNJ) revised their earnings estimates. While 2011 estimates have been revised in both directions, 2012 estimates have gone predominantly downwards. Third Quarter Recap Johnson &#38; Johnson posted third quarter 2011 earnings (excluding special items) of $1.24 per share, three cents above the Zacks Consensus Estimate of $1.21 and 0.8% above the year-ago earnings of $1.23. Johnson &#38; Johnson’s revenues for the reported quarter increased 6.8% year-over-year to $16 billion. Revenues were in-line with the Zacks Consensus Estimate. Operational factors and foreign exchange movement favorably impacted sales by 2.6% and 4.2%, respectively. Including one-time items, Johnson &#38; Johnson reported earnings of $1.15, 6.5% below the year-ago earnings of $1.23. Agreement of Analysts Estimates for fiscal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/06/jnj-johnson-johnson-2011-third-quarter-earnings-scorecard/86234/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck Drug Candidate Presents New Data</title>
		<link>http://www.stockbloghub.com/2011/09/21/mrk-merck-drug-candidate-presents-new-data/83706</link>
		<comments>http://www.stockbloghub.com/2011/09/21/mrk-merck-drug-candidate-presents-new-data/83706#comments</comments>
		<pubDate>Wed, 21 Sep 2011 18:08:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83706</guid>
		<description><![CDATA[Merck (MRK) recently presented new clinical and pre-clinical data on its phase III pipeline candidate, odanacatib. Odanacatib is an investigational cathepsin K (cat-K) inhibitor which is being developed for the treatment of osteoporosis in post-menopausal women. Results were presented from a phase IIb clinical study extending to five years. Merck said that postmenopausal women being treated with odanacatib 50 mg weekly continuously for five years experienced an increase in bone mass density (BMD) at the lumbar spine (11.9% increase from baseline), femoral neck (9.8% increase from baseline), hip trochanter (10.9% increase from baseline), and total hip (8.5% increase from baseline). However, adverse and serious adverse experiences were higher in the odanacatib treatment group. Adverse experiences and serious adverse experiences were 89% and 22%, respectively in the odanacatib arm, compared to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/21/mrk-merck-drug-candidate-presents-new-data/83706/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Coverage Initiated at Neutral</title>
		<link>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692</link>
		<comments>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692#comments</comments>
		<pubDate>Wed, 21 Sep 2011 14:56:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83692</guid>
		<description><![CDATA[We are initiating coverage on AstraZeneca (AZN) with a Neutral recommendation and a target price of $47.00. AstraZeneca, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca’s business can be broken down into separate lines based on therapeutic classes. These include: gastrointestinal, cardiovascular, respiratory and inflammation, oncology, neuroscience, infection and other. The company’s key products include Crestor (cholesterol management); Nexium (acid reflux); Seroquel (schizophrenia and bipolar mania); Atacand (hypertension and symptomatic heart failure), Arimidex (breast cancer), Zoladex (prostate and breast cancer) and Symbicort (asthma). We are impressed by the performance of lead drug Crestor which is primarily responsible for AstraZeneca being one of the leading players in the global cardiovascular market. The US launch of Brilinta (ticagrelor) for the reduction of the rate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Presents HCV Data</title>
		<link>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567</link>
		<comments>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567#comments</comments>
		<pubDate>Tue, 20 Sep 2011 19:50:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83567</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) presented encouraging data from a phase II study (n=48) which evaluated its candidate BMS-790052 in combination with peginterferon and ribavirin (standards of care) for treating patients suffering from the hepatitis C virus (HCV). Bristol-Myers presented data from the mid-stage study at the 51st interscience conference on antimicrobial agents and chemotherapy held in the US. The double-blind study evaluated BMS-790052 at three doses (3 mg, 10 mg or 60 mg) in treatment-naïve patients infected with genotype 1 chronic HCV. Results from the study revealed that the rate of SVR24 (sustained virologic response – absence of detectable HCV at 24 weeks post treatment ) achieved by patients treated with a combination of BMS-790052, PEG-interferon alfa and ribavirin was higher across all evaluated doses than those receiving placebo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Drug Cleared in European Union for SEGA</title>
		<link>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127</link>
		<comments>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127#comments</comments>
		<pubDate>Tue, 20 Sep 2011 19:12:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83127</guid>
		<description><![CDATA[Novartis (NVS) recently received a boost when its drug Votubia was approved for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS) in the European Union (EU). For the first time ever will such a medication be available in this region for the treatment of this challenging disease. Votubia is already marketed in the US under the trade name Afinitor for the disease. It is also approved in Switzerland, Brazil, Colombia, Guatemala, the Philippines and South Korea to treat SEGA associated with TS. Earlier in June this year, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Votubia for the indication. The recommendation was based on data from a mid-stage study, which showed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca&#8217;s Brilinta Now in US</title>
		<link>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949</link>
		<comments>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949#comments</comments>
		<pubDate>Thu, 15 Sep 2011 17:47:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81949</guid>
		<description><![CDATA[AstraZeneca plc (AZN) recently announced the US launch of Brilinta (ticagrelor). The drug was approved by the US Food and Drug Administration (FDA) last month, to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS). Following the launch, AstraZeneca plans to work with distribution partners and pharmacy customers to ensure that Brilinta is readily available for use. The regulatory body’s approval was based on the PLATO study, which compared Brilinta to clopidogrel in 18,624 patients suffering from ACS. The study demonstrated that there was no statistical difference in adverse reactions observed among patients treated with Brilinta, compared to those treated with clopidogrel. Clopidogrel, which is marketed worldwide by Bristol-Myers Squibb &#38; Co. (BMY) and Sanofi-Aventis (SNY) under the brand name Plavix, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb and Pfizer Get Encouraging Data</title>
		<link>http://www.stockbloghub.com/2011/09/14/bmy-bristol-myers-squibb-and-pfizer-get-encouraging-data/82258</link>
		<comments>http://www.stockbloghub.com/2011/09/14/bmy-bristol-myers-squibb-and-pfizer-get-encouraging-data/82258#comments</comments>
		<pubDate>Wed, 14 Sep 2011 16:41:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82258</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner Eliquis (apixaban) in patients suffering from erratic heartbeat and carrying at least one additional risk factor for stroke. The cardiac rhythm disorder is referred to as atrial fibrillation (AF). Bristol-Myers and Pfizer presented detailed data from the study at the European Society of Cardiology. Topline results were presented in June 2011. Apixaban will be marketed under the trade name Eliquis in the EU. The same trade name has been proposed in the US. Data from the randomized, double-blind, multicenter study revealed that Eliquis was non-inferior to the standard therapy warfarin in reducing the risk of stroke or systemic embolism. Patients treated with Eliquis were 21% less likely ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/14/bmy-bristol-myers-squibb-and-pfizer-get-encouraging-data/82258/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Neuroendocrine Tumors Drug Cleared in European Union</title>
		<link>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655</link>
		<comments>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655#comments</comments>
		<pubDate>Sun, 11 Sep 2011 19:54:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Arlington Asset Investment Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82655</guid>
		<description><![CDATA[Novartis’(NVS) drug Afinitor was recently approved in the European Union (EU) for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin with progressive disease. The drug is already approved in the US for the indication. The approval was based on the RADIANT-3 trial which demonstrated that Afinitor led to a statistically significant improvement in progression-free survival versus placebo. The number of months of survival without the disease progressing was 11 months for a patient treated with Afinitor versus 4.6 months for a patient on placebo. Afinitor is currently marketed for the treatment of advanced renal cell carcinoma (kidney cancer) after an anti-VEGF therapy like Roche’s (RHHBY) Avastin, Pfizer’s (PFE) Sutent or Onyx Pharmaceuticals’(ONXX) Nexavar in the US and EU. In June this year, the Committee for Medicinal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Reports Solid Quarter</title>
		<link>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092</link>
		<comments>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092#comments</comments>
		<pubDate>Wed, 03 Aug 2011 19:53:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80092</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) second quarter 2011 earnings (excluding special items) of $0.56 per share surpassed the Zacks Consensus Estimate by $0.01and the year-ago earnings by $0.02. Higher revenues boosted earnings in the reported quarter. On a reported basis (including special items), Bristol-Myers’ earnings in the quarter decreased 2% to $0.52 per share. The healthcare reform enacted in 2010 negatively impacted earnings in the reported quarter by $0.03. Net sales in the reported quarter climbed 14% to $5.4 billion. Foreign exchange positively impacted sales in the quarter by 4%. Revenues also surpassed the Zacks Consensus Estimate of $5.0 billion, driven by the impressive showing of Bristol-Myers’ lead drugs including blood thinner Plavix. US net sales in the quarter climbed 15% to $3.6 billion. Sales in international markets increased 13% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Stock Market News for August 2, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/08/02/abt-stock-market-news-for-august-2-2011-market-news/80404</link>
		<comments>http://www.stockbloghub.com/2011/08/02/abt-stock-market-news-for-august-2-2011-market-news/80404#comments</comments>
		<pubDate>Tue, 02 Aug 2011 21:22:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AET]]></category>
		<category><![CDATA[Aetna Inc.]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[Kratos Defense & Security Solutions Inc]]></category>
		<category><![CDATA[KTOS]]></category>
		<category><![CDATA[LMT]]></category>
		<category><![CDATA[Lockheed Martin Corporation]]></category>
		<category><![CDATA[NOC]]></category>
		<category><![CDATA[Northrop Grumman Corporation]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80404</guid>
		<description><![CDATA[The benchmarks’ roller-coaster ride finally came to a stop with markets losing modest points, as manufacturing data spoiled the party after Obama and congressional leaders confirmed they had reached an agreement on the debt ceiling. Investor mood swayed from positive to cautious after disappointing ISM data and uncertainty prevailed ahead of the lawmakers vote on the borrowing limit issue. The Dow Jones Industrial Average (DJIA) lost 10 points, or 0.1% to settle at 12,132.49. Earlier the blue-chip index had soared almost 140 points riding on the announcement by President Obama and the congressional heads. However, these gains were washed out by disappointing manufacturing data. The Standard &#38; Poor 500 (S&#38;P 500) shed 0.4% to close at 1,286.94. The Nasdaq Composite Index also lost 0.4% and finished the day at 2,744.61. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/02/abt-stock-market-news-for-august-2-2011-market-news/80404/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Presents Afinitor Data</title>
		<link>http://www.stockbloghub.com/2011/07/12/nvs-novartis-presents-afinitor-data/78847</link>
		<comments>http://www.stockbloghub.com/2011/07/12/nvs-novartis-presents-afinitor-data/78847#comments</comments>
		<pubDate>Tue, 12 Jul 2011 16:58:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78847</guid>
		<description><![CDATA[Recently, Novartis (NVS) presented data from a late-stage study (EXIST-1) of its cancer drug Afinitor (everolimus). The randomized, placebo-controlled, double-blind, multicenter study evaluated the safety and effectiveness of the drug compared to placebo for treating patients with subependymal giant cell astrocytomas (SEGAs) coupled with tuberous sclerosis (TS). Results from the study were presented at the International tuberous sclerosis complex (TSC) Research Conference in the US. The study revealed that treatment with Afinitor caused a 50% or more reduction in SEGA tumor size in 35% of the patients. However, no such reduction was observed in the placebo arm. SEGA refers to a benign brain tumor associated with tuberous sclerosis. TSC, which is associated with multiple disorders such as seizures, swelling in the brain, developmental delays and skin lesions, affects approximately one ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/12/nvs-novartis-presents-afinitor-data/78847/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis AG&#8217;s Lung Drug Cleared in US</title>
		<link>http://www.stockbloghub.com/2011/07/11/nvs-novartis-ags-lung-drug-cleared-in-us/78600</link>
		<comments>http://www.stockbloghub.com/2011/07/11/nvs-novartis-ags-lung-drug-cleared-in-us/78600#comments</comments>
		<pubDate>Mon, 11 Jul 2011 15:55:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78600</guid>
		<description><![CDATA[Novartis AG (NVS) recently announced that its once-daily long-acting beta2-agonist (LABA) Arcapta Neohaler (75 mcg) was cleared by the US Food and Drug Administration (FDA) for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. With the approval, Arcapta becomes the first therapy in the LABA class to be approved for the indication in the US. Arcapta is already available in 150 and 300 mcg versions, under the brand name of Onbrez Breezhaler (also known as QAB 149), in the European Union. Onbrez Breezhaler (150 mcg) was also cleared in Japan recently for relief of symptoms due to airway obstruction in COPD (chronic bronchitis and emphysema). It is now approved in more than 60 countries and available in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/11/nvs-novartis-ags-lung-drug-cleared-in-us/78600/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Japanese Approval for Merck Products</title>
		<link>http://www.stockbloghub.com/2011/07/11/mrk-japanese-approval-for-merck-products/78598</link>
		<comments>http://www.stockbloghub.com/2011/07/11/mrk-japanese-approval-for-merck-products/78598#comments</comments>
		<pubDate>Mon, 11 Jul 2011 15:54:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78598</guid>
		<description><![CDATA[Merck (MRK) recently announced that it received approval for three products in Japan. The Japanese Ministry of Health, Labour and Welfare (MHLW) approved Gardasil [human papillomavirus quadrivalent (Types 6, 11, 16 and 18) vaccine, recombinant], Zolinza (vorinostat) and Cubicin (daptomycin for injection) for use in Japan. Gardasil gained approval for the prevention of cervical cancer (squamous cell cancer and adenocarcinoma) and their precursor lesions (cervical intraepithelial neoplasm grade 1/2/3 and cervical adenocarcinoma in situ), vulvar intraepithelial neoplasia grade 1/2/3, vaginal intraepithelial neoplasia grade 1/2/3 and genital warts caused by HPV types 6, 11, 16 and 18 in females 9 years of age and older. Meanwhile, Zolinza gained approval for the treatment of cutaneous T-cell lymphomas. Cubicin, an antibacterial agent with activity against methicillin-resistant Staphylococcus aureus (MRSA), gained approval for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/11/mrk-japanese-approval-for-merck-products/78598/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis AG&#8217;s Afinitor Impresses Again</title>
		<link>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554</link>
		<comments>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554#comments</comments>
		<pubDate>Thu, 07 Jul 2011 17:02:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PFS]]></category>
		<category><![CDATA[Provident Financial Services Inc]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78554</guid>
		<description><![CDATA[It seems Novartis AG’s (NVS) breast cancer drug, Afinitor (everolimus), is getting into a habit of delivering positive news. Right after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Afinitor last week for the treatment of subependymal giant cell astrocytomas (SEGA), the drug impressed again this week with positive interim results from a pivotal late-stage trial (BOLERO-2). BOLERO-2 evaluated Afinitor in combination with exemestane versus placebo plus exemestane in postmenopausal women with estrogen receptor-positive locally-advanced breast cancer, whose disease progressed, despite treatment with the nonsteroidal aromatase inhibitors letrozole or anastrozole. The trial results demonstrated that patients with advanced breast cancer who were dosed Afinitor in combination with exemestane, experienced significantly extended progression-free survival (PFS), as compared to patients who received ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Boost for Bayer and Johnson &amp; Johnson</title>
		<link>http://www.stockbloghub.com/2011/07/05/jnj-boost-for-bayer-and-johnson-johnson/78369</link>
		<comments>http://www.stockbloghub.com/2011/07/05/jnj-boost-for-bayer-and-johnson-johnson/78369#comments</comments>
		<pubDate>Wed, 06 Jul 2011 00:07:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78369</guid>
		<description><![CDATA[Recently, the US Food and Drug Administration (FDA) delivered a huge boost for Bayer (BAYRY) and partner Johnson &#38; Johnson (JNJ) by clearing their blood-thinner (anticoagulant) Xarelto (rivaroxaban). The US regulatory body cleared the drug, which has blockbuster potential, for the prevention of deep vein thrombosis (DVT) which may cause pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery.  The blood-thinner is already available in Europe for the indication. The current approval will allow Xarelto to be marketed in the US as a once-daily tablet (10 mg). The tablet is to be taken for 35 days after hip replacement and for 12 days after knee replacement. The US approval was based on late-stage studies which showed that Xarelto was more effective than Sanofi-Aventis’ (SNY) Lovenox (enoxaparin). Moreover, Xarelto ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/jnj-boost-for-bayer-and-johnson-johnson/78369/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly Provides Research and Development Update</title>
		<link>http://www.stockbloghub.com/2011/07/05/lly-eli-lilly-provides-research-and-development-update/78330</link>
		<comments>http://www.stockbloghub.com/2011/07/05/lly-eli-lilly-provides-research-and-development-update/78330#comments</comments>
		<pubDate>Tue, 05 Jul 2011 16:34:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78330</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) recently provided an insight into its research and development (R&#38;D) plans and mid-term guidance at a meeting with the investment community. The company outlined its plans for combating the impact of the patent expiration of several key products. About $7 billion of revenues will be lost to generic competition due to the loss of exclusivity of products like Zyprexa, Cymbalta, Evista, and Gemzar. Pipeline to Drive Long-Term Growth Eli Lilly intends to continue spending significantly on its pipeline. The company expects to spend about 25% of revenues on its R&#38;D efforts.  Eli Lilly currently has about 70 candidates in its pipeline including 33 candidates in phase II and III stages of development. The company expects to launch several candidates through 2017 and is on track ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/lly-eli-lilly-provides-research-and-development-update/78330/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson &amp; Johnson Recalls Tylenol Lot</title>
		<link>http://www.stockbloghub.com/2011/06/30/jnj-johnson-johnson-recalls-tylenol-lot/77969</link>
		<comments>http://www.stockbloghub.com/2011/06/30/jnj-johnson-johnson-recalls-tylenol-lot/77969#comments</comments>
		<pubDate>Thu, 30 Jun 2011 21:28:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CAI International Inc.]]></category>
		<category><![CDATA[CAP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77969</guid>
		<description><![CDATA[Johnson &#38; Johnson (JNJ) recently announced that it is recalling one lot of Tylenol Extra Strength Caplets, 225 count bottles, at the retail level. The lot, manufactured in Feb 2009, is being recalled in the US. The recall was initiated due to reports regarding odor including musty, moldy odor. Product recalls remain a frequent occurrence at Johnson &#38; Johnson. Products that were recalled by the company over the past few quarters include Tylenol, Benadryl, Motrin, Rolaids, Invega Sustenna, Simponi and Sudafed Pe among others. Earlier this month, the company had recalled one lot of Risperdal (risperidone) and one lot of a 2mg generic version of the product. Frequent product recalls adversely affected the performance of Johnson &#38; Johnson’s Consumer Healthcare segment in 2010. In fact, Consumer segment sales declined 7.7% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/30/jnj-johnson-johnson-recalls-tylenol-lot/77969/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Expands HIV Drug&#8217;s Reach</title>
		<link>http://www.stockbloghub.com/2011/06/30/bmy-bristol-myers-squibb-expands-hiv-drugs-reach/78060</link>
		<comments>http://www.stockbloghub.com/2011/06/30/bmy-bristol-myers-squibb-expands-hiv-drugs-reach/78060#comments</comments>
		<pubDate>Thu, 30 Jun 2011 20:41:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78060</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) inked a deal with Mylan Inc. (MYL) to expand the market for its HIV drug Reyataz (atazanavir sulfate). The deal allows Matrix to develop and sell the generic version of the HIV therapy in the Indian and sub-Saharan African markets. Apart from Reyataz, Mylan will also sell the generic versions of other Bristol-Myers HIV therapies such as Videx (didanosine) and Zerit (stavudine) in the above territories as per the agreement. The transaction marks the fifteenth deal signed by Bristol-Myers in the field of HIV and the fourth deal involving Reyataz. The deal also promises the pediatric versions of the HIV therapies. The deal permits Mylan’s Matrix Laboratories to secure prequalification from the World Health Organization (WHO) for all the offerings covered by the deal. This ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/30/bmy-bristol-myers-squibb-expands-hiv-drugs-reach/78060/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer Drug Accepted for Standard FDA Review</title>
		<link>http://www.stockbloghub.com/2011/06/30/pfe-pfizer-drug-accepted-for-standard-fda-review/78034</link>
		<comments>http://www.stockbloghub.com/2011/06/30/pfe-pfizer-drug-accepted-for-standard-fda-review/78034#comments</comments>
		<pubDate>Thu, 30 Jun 2011 20:38:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RCC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78034</guid>
		<description><![CDATA[Pfizer Inc. (PFE) recently announced that its regulatory application for oncology candidate, axitinib has been accepted for standard review by the US Food and Drug Administration (FDA). The company is seeking approval for the treatment of patients with advanced renal cell carcinoma (RCC). The regulatory application was based on data from the phase III AXIS 1032 study which compared axitinib with Onyx Pharmaceuticals/Bayer’s (ONXX/BAYRY) Nexavar (sorafenib). Earlier this month, the European Medicines Agency (EMA) also accepted Pfizer’s regulatory filing for axitinib. Pfizer is seeking EU approval for the use of axitinib in treatment-failed patients with advanced renal cell carcinoma. The approval of axitinib would provide advanced renal cell carcinoma patients, especially previously-treated patients, with an additional treatment option. According to Pfizer, kidney cancer is diagnosed in about 210,000 people every ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/30/pfe-pfizer-drug-accepted-for-standard-fda-review/78034/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis AG Afinitor Backed in EU</title>
		<link>http://www.stockbloghub.com/2011/06/29/nvs-novartis-ag-afinitor-backed-in-eu/77906</link>
		<comments>http://www.stockbloghub.com/2011/06/29/nvs-novartis-ag-afinitor-backed-in-eu/77906#comments</comments>
		<pubDate>Wed, 29 Jun 2011 20:55:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Arlington Asset Investment Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77906</guid>
		<description><![CDATA[Novartis AG (NVS) received a boost recently when the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of its drug Afinitor for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS), in the European Union. The European Commission is expected to give its decision within the next three months. The drug will be marketed in the EU in the trade name of Votubia and will be the first medicine in the region for the treatment of this challenging disease, if approved. It is already marketed in the US as Afinitor for the disease. It is also approved in Switzerland Brazil, Colombia, Guatemala, the Philippines and South Korea to treat SEGA associated with TS. Novartis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/nvs-novartis-ag-afinitor-backed-in-eu/77906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs and Reata Pharmaceuticals Present New Phase II Data</title>
		<link>http://www.stockbloghub.com/2011/06/29/abt-abbott-labs-and-reata-pharmaceuticals-present-new-phase-ii-data/77768</link>
		<comments>http://www.stockbloghub.com/2011/06/29/abt-abbott-labs-and-reata-pharmaceuticals-present-new-phase-ii-data/77768#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:43:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Marshall & Ilsley Corporation]]></category>
		<category><![CDATA[MI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77768</guid>
		<description><![CDATA[Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently announced the presentation of new phase II data on bardoxolone methyl. In addition to being posted online in The New England Journal of Medicine, the data were also presented at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress. The phase II BEAM study was conducted in patients with moderate to severe chronic kidney disease and type II diabetes. Results showed that patients receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period as measured by estimated glomerular filtration rate (eGFR), which is an important measure of kidney function. All three doses (25, 75 or 150 mg) of bardoxolone methyl achieved a statistically significant improvement in eGFR compared to placebo. Moreover, only 9% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/abt-abbott-labs-and-reata-pharmaceuticals-present-new-phase-ii-data/77768/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Presents Data on Two Studies</title>
		<link>http://www.stockbloghub.com/2011/06/29/bmy-bristol-myers-squibb-company-presents-data-on-two-studies/77782</link>
		<comments>http://www.stockbloghub.com/2011/06/29/bmy-bristol-myers-squibb-company-presents-data-on-two-studies/77782#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:34:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77782</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner AstraZeneca (AZN) presented encouraging data from two late-stage studies which evaluated their type II diabetes candidate dapagliflozin in conjunction with the extended-release version of metformin (XR). Data from the two 24-week studies, which evaluated adults suffering from type II diabetes, were presented at the American Diabetes Association (ADA) Scientific Sessions. Data from the studies revealed that there was a significant reduction in blood sugar levels in patients treated with dapagliflozin and metformin XR versus those treated with dapagliflozin or metformin XR alone and placebo. Moreover, no major events related to hypoglycemia were reported in the studies. Hypoglycemia refers to the situation of abnormally low levels of glucose in the blood. Results also revealed that patients treated with the combination of dapagliflozin and metformin ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/bmy-bristol-myers-squibb-company-presents-data-on-two-studies/77782/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer and Pain Therapeutics Get Bad News for Remoxy</title>
		<link>http://www.stockbloghub.com/2011/06/27/pfe-pfizer-and-pain-therapeutics-get-bad-news-for-remoxy/77578</link>
		<comments>http://www.stockbloghub.com/2011/06/27/pfe-pfizer-and-pain-therapeutics-get-bad-news-for-remoxy/77578#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:48:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77578</guid>
		<description><![CDATA[The US Food and Drug Administration recently dealt a blow to Pfizer (PFE) and Pain Therapeutics, Inc. (PTIE) by issuing a second complete response letter (CRL) for their opioid candidate, Remoxy. Remoxy became a part of Pfizer’s pipeline following its acquisition of King Pharmaceuticals earlier this year. Remoxy has been developed, using Durect Corporation’s (DRRX) ORADUR technology, for moderate to severe pain that requires continuous, around-the-clock opioid treatment for an extended period of time. The CRL is a major setback for Pain Therapeutics and Durect Corp. While Pain Therapeutics’ shares dropped more than 40% on the news, Durect’s shares were down 31%. Second CRL for Remoxy Remoxy’s regulatory path has not been smooth with the candidate receiving a second CRL from the FDA. King Pharma had initially submitted the Remoxy ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/pfe-pfizer-and-pain-therapeutics-get-bad-news-for-remoxy/77578/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer&#8217;s Lyrica Holds Promise</title>
		<link>http://www.stockbloghub.com/2011/06/26/pfe-pfizers-lyrica-holds-promise/77400</link>
		<comments>http://www.stockbloghub.com/2011/06/26/pfe-pfizers-lyrica-holds-promise/77400#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:31:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77400</guid>
		<description><![CDATA[Pfizer Inc. (PFE) recently presented positive top-line data on its blockbuster drug, Lyrica. Pfizer said that Lyrica met the primary endpoint in a study that was being conducted in patients with chronic central neuropathic pain following traumatic spinal cord injury. Patients participating in the double-blind, placebo-controlled, parallel group, multi-center study (Study A0081107) were randomized to receive Lyrica or placebo. Initial results showed that Lyrica demonstrated positive efficacy in reducing central neuropathic pain following spinal cord injury compared to placebo. Pfizer will analyze the data further. Pfizer has been working on expanding Lyrica’s label for additional indications. Lyrica has experienced a very strong ramp since its introduction. Total Lyrica sales in 2010 were $3.0 billion. The product is approved in 110 countries and regions for indications like diabetic nerve pain, pain ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/pfe-pfizers-lyrica-holds-promise/77400/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs Boosts Immunology Pipeline</title>
		<link>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422</link>
		<comments>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422#comments</comments>
		<pubDate>Fri, 24 Jun 2011 22:04:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77422</guid>
		<description><![CDATA[Abbott Labs (ABT) recently entered into a global agreement with Biotest AG for the development and commercialization of a novel anti-CD4 antibody, BT-061. The Candidate: BT-061 The deal is focused on the development and commercialization of BT-061 for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently being evaluated in phase II studies for RA and psoriasis. Moreover, the candidate’s potential to be used for other immune-related diseases is being evaluated in preclinical studies. BT-061 could be differentiated from other anti-CD4 antibodies as it does not cause depletion of CD4 positive T-cells which would lead to weakened immune responses. Terms of the Deal Per the terms of the agreement, BT-061 will be co-promoted by Abbott Labs and Biotest in the five major European markets: Germany, France, United Kingdom, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb and Pfizer Report Positive Data on Blood Thinner Apixaban Drug</title>
		<link>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318</link>
		<comments>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:18:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77318</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging top line data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner apixaban in patients suffering from an erratic heartbeat. This cardiac rhythm disorder is referred to as atrial fibrillation (AF). Apixaban will be marketed under the trade name Eliquis in the EU. The same trade name has been proposed in the US and other countries. Top-line results from the double-blind, multicenter study revealed that Eliquis was non-inferior to the standard therapy warfarin with respect to the combined outcome of stroke and systemic embolism. Data further revealed that Eliquis was superior to warfarin with respect to effectiveness and major bleeding. Bristol-Myers and Pfizer intend to seek approval from the US Food and Drug Administration (FDA) and also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer and Acura Pharmaceuticals Win FDA Approval for Oxecta</title>
		<link>http://www.stockbloghub.com/2011/06/23/pfe-pfizer-and-acura-pharmaceuticals-win-fda-approval-for-oxecta/77271</link>
		<comments>http://www.stockbloghub.com/2011/06/23/pfe-pfizer-and-acura-pharmaceuticals-win-fda-approval-for-oxecta/77271#comments</comments>
		<pubDate>Thu, 23 Jun 2011 20:12:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77271</guid>
		<description><![CDATA[Pfizer Inc. (PFE) and partner Acura Pharmaceuticals Inc. (ACUR) recently received US Food and Drug Administration (FDA) approval for their pain treatment, Oxecta (oxycodone). Oxecta (formerly known as Acurox) gained approval for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. Oxecta became a part of Pfizer’s portfolio following its acquisition of King Pharma earlier this year. Oxecta has been developed under an agreement for the licensing, development, and commercialization of immediate release (IR) pain medicines utilizing Acura&#8217;s Aversion (abuse-deterrent) technology. The abuse-deterrent technology has been designed to discourage opioid abuse and misuse through common ways of tampering. Oxecta’s approval triggers a $20 million milestone payment to Acura from Pfizer. Remoxy Action Date Round the Corner Pfizer has another important ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/pfe-pfizer-and-acura-pharmaceuticals-win-fda-approval-for-oxecta/77271/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Gets Setback From FDA Panel</title>
		<link>http://www.stockbloghub.com/2011/06/22/nvs-novartis-gets-setback-from-fda-panel/77188</link>
		<comments>http://www.stockbloghub.com/2011/06/22/nvs-novartis-gets-setback-from-fda-panel/77188#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:03:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CAPS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Orthologic Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77188</guid>
		<description><![CDATA[Novartis (NVS) received a setback recently when an advisory panel to the US Food and Drug Administration (FDA) recommended against approving its pipeline candidate ACZ885 for the proposed indication. Novartis was seeking approval to expand the use of ACZ885 for the treatment of patients suffering from severe gouty arthritis, commonly known as gout, who failed to derive adequate relief from the currently available options like non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine. ACZ885 is currently marketed for the treatment of cryopyrin-associated periodic syndromes (CAPS) under the trade name Ilaris. In Japan, however, the drug is under review for this indication. The panel strongly backed the efficacy but was concerned about safety of ACZ885. The panel believes the candidate can be used in a narrower patient population. The panel’s recommendation was based ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/nvs-novartis-gets-setback-from-fda-panel/77188/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer&#8217;s Chantix Could Increase Heart Risk</title>
		<link>http://www.stockbloghub.com/2011/06/21/pfe-pfizers-chantix-could-increase-heart-risk/76842</link>
		<comments>http://www.stockbloghub.com/2011/06/21/pfe-pfizers-chantix-could-increase-heart-risk/76842#comments</comments>
		<pubDate>Tue, 21 Jun 2011 18:59:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76842</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) recently announced that Pfizer’s (PFE) smoking cessation aid Chantix (varenicline) could be linked with a small, increased risk of certain cardiovascular adverse events in patients with cardiovascular disease. The FDA’s announcement was based on a review of data from a randomized, double-blind, placebo-controlled study that was conducted to evaluate the safety and efficacy of Chantix for smoking cessation. The study was conducted with about 700 patients (35 – 75 years old). While Chantix was found to be effective in helping patients quit smoking and maintain abstinence for about a year, certain cardiovascular events (like angina pectoris, non fatal myocardial infarction, need for coronary revascularization, and new diagnosis of peripheral vascular disease or admission for a procedure for the treatment of peripheral vascular disease) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/21/pfe-pfizers-chantix-could-increase-heart-risk/76842/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ$) Johnson &amp; Johnson Recalls Risperdal Lot</title>
		<link>http://www.stockbloghub.com/2011/06/21/jnj-johnson-johnson-recalls-risperdal-lot/76828</link>
		<comments>http://www.stockbloghub.com/2011/06/21/jnj-johnson-johnson-recalls-risperdal-lot/76828#comments</comments>
		<pubDate>Tue, 21 Jun 2011 18:57:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CAI International Inc.]]></category>
		<category><![CDATA[CAP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76828</guid>
		<description><![CDATA[Johnson &#38; Johnson (JNJ) recently announced that it is voluntarily recalling one lot of Risperdal (risperidone) and one lot of a 2mg generic version of the product. The recalls were based on reports regarding an uncharacteristic odor, which could have been caused by trace amounts of TBA (2,4,6 tribromoanisole). The recalls were announced in the US and Puerto Rico. While the Risperdal recall relates to 16,000 bottles that were shipped between Aug 27, 2010 and Feb 15, 2011, the risperidone recall relates to 24,000 bottles shipped between Nov 10, 2010 and Jan 1, 2011. Johnson &#38; Johnson estimates that approximately 1,600 and 1,200 bottles of the affected lot of Risperdal and risperidone, respectively, remain in the market. The company does not expect any supply constraints due to the recalls. Product ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/21/jnj-johnson-johnson-recalls-risperdal-lot/76828/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs&#8217; Bardoxolone in Phase III Trials</title>
		<link>http://www.stockbloghub.com/2011/06/19/abt-abbott-labs-bardoxolone-in-phase-iii-trials/76721</link>
		<comments>http://www.stockbloghub.com/2011/06/19/abt-abbott-labs-bardoxolone-in-phase-iii-trials/76721#comments</comments>
		<pubDate>Sun, 19 Jun 2011 17:25:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Marshall & Ilsley Corporation]]></category>
		<category><![CDATA[MI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76721</guid>
		<description><![CDATA[Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently commenced a pivotal phase III study with bardoxolone methyl. Bardoxolone methyl’s safety and efficacy will be evaluated in patients with chronic kidney disease and type II diabetes. Study Design The multinational, double-blind, placebo-controlled phase III study, BEACON (Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes: the Occurrence of renal eveNts), will be conducted with about 1,600 patients across 300 sites. Patients will be randomized 1:1 to receive either a 20 mg reformulated version of bardoxolone methyl or placebo once daily. While the primary efficacy endpoint is a time-to-first-event composite consisting of progression to end-stage renal disease (ESRD) and cardiovascular death, secondary endpoints include change in estimated glomerular filtration rate (eGFR) and a time-to-first-event composite consisting of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/abt-abbott-labs-bardoxolone-in-phase-iii-trials/76721/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly Launches Type II Diabetes Treatment Tradjenta</title>
		<link>http://www.stockbloghub.com/2011/06/17/lly-eli-lilly-launches-type-ii-diabetes-treatment-tradjenta/76604</link>
		<comments>http://www.stockbloghub.com/2011/06/17/lly-eli-lilly-launches-type-ii-diabetes-treatment-tradjenta/76604#comments</comments>
		<pubDate>Fri, 17 Jun 2011 14:50:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[RAD]]></category>
		<category><![CDATA[Rite Aid Corporation]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76604</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) and partner Boehringer Ingelheim Pharmaceuticals, Inc. recently announced that their type II diabetes treatment, Tradjenta (linagliptin) is now available in pharmacies across the US. Tradjenta, which has been priced at $6.77 per tablet, is available at Walgreen (WAG), CVS Caremark Corp. (CVS), Rite Aid Corp. (RAD) and several other leading chain and independent pharmacies as well. Eli Lilly and Boehringer are working on gaining formulary coverage for the product and are looking to get Tradjenta reimbursed at a co-pay level similar to other preferred branded products. Eli Lilly and Boehringer’s strategic alliance, signed in Jan 2011, is focused on bringing new diabetes treatments to market. However, in May 2011, Eli Lilly’s exenatide partner, Amylin Pharmaceuticals, Inc. (AMLN) filed a lawsuit against Eli Lilly. Amylin claimed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/17/lly-eli-lilly-launches-type-ii-diabetes-treatment-tradjenta/76604/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Gets Another Feather in its Cap</title>
		<link>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633</link>
		<comments>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633#comments</comments>
		<pubDate>Fri, 17 Jun 2011 14:42:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76633</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) product portfolio was boosted further when the US Food and Drug Administration (FDA) approved its drug Nulojix (belatacept) to prevent the rejection of transplanted kidneys in adults. We remind investors that Bristol-Myers has succeeded in getting the drug approved in the US for the indication in its second attempt. In the second quarter of 2010, the FDA issued a complete response letter in response to biologic license application (BLA) submitted by the pharma major for Nulojix , asking for additional information. Subsequently, Bristol-Myers submitted it. In December 2010, the agency had thereby announced that it would review the re-submitted application by June 15, 2011 (action date). The agency cleared the drug following the review thereby delivering a further boost to the company. We note that the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson &amp; Johnson to Discontinue Cypher Stent</title>
		<link>http://www.stockbloghub.com/2011/06/16/jnj-johnson-johnson-to-discontinue-cypher-stent/76575</link>
		<comments>http://www.stockbloghub.com/2011/06/16/jnj-johnson-johnson-to-discontinue-cypher-stent/76575#comments</comments>
		<pubDate>Thu, 16 Jun 2011 21:59:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[El Paso Corporation]]></category>
		<category><![CDATA[EP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[WisdomTree SmallCap Dividend]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76575</guid>
		<description><![CDATA[Cordis Corporation, a Johnson &#38; Johnson (JNJ) company, recently announced that it will stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents by year end. The company will also discontinue the development of Nevo sirolimus-eluting coronary stent. Cordis intends to focus on other cardiovascular therapies instead. Cypher Sales Were Under Pressure The decision to discontinue Cypher stent does not come as a surprise given the declining sales of the product. Changing dynamics in the drug-eluting stent (DES) market along with unlicensed competition from products infringing Cordis’ patents led to an erosion in Cypher stent’s pricing, sales and market share. Moreover, the launch of superior products by competitors also led to a loss of market share. On the first quarter call, Johnson &#38; Johnson reported a 41% decline in Cypher ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/jnj-johnson-johnson-to-discontinue-cypher-stent/76575/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

